Advertisement
Policy Forum

Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers

  • Andrew J. Prendergast mail,

    a.prendergast@qmul.ac.uk

    Affiliations: Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, United Kingdom, MRC Clinical Trials Unit, London, United Kingdom, Zvitambo Project, Harare, Zimbabwe

    X
  • Martina Penazzato,

    Affiliation: MRC Clinical Trials Unit, London, United Kingdom

    X
  • Mark Cotton,

    Affiliation: Children's Infectious Disease Clinical Research Unit, Faculty of Health Sciences, Stellenbosch University and Tygerberg Children's Hospital, Tygerberg, South Africa

    X
  • Philippa Musoke,

    Affiliation: Mulago Hospital, Paediatric Infectious Diseases Clinic, Kampala, Uganda

    X
  • Veronica Mulenga,

    Affiliation: University Teaching Hospital, Lusaka, Zambia

    X
  • Elaine J. Abrams,

    Affiliation: ICAP, Mailman School of Public Health and College of Physicians & Surgeons, Columbia University, New York, New York, United States of America

    X
  • Diana M. Gibb

    Affiliation: MRC Clinical Trials Unit, London, United Kingdom

    X
  • Published: July 24, 2012
  • DOI: 10.1371/journal.pmed.1001273

About the Authors

Andrew J. Prendergast
Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, United Kingdom
Andrew J. Prendergast, Martina Penazzato, Diana M. Gibb
MRC Clinical Trials Unit, London, United Kingdom
Andrew J. Prendergast
Zvitambo Project, Harare, Zimbabwe
Mark Cotton
Children's Infectious Disease Clinical Research Unit, Faculty of Health Sciences, Stellenbosch University and Tygerberg Children's Hospital, Tygerberg, South Africa
Philippa Musoke
Mulago Hospital, Paediatric Infectious Diseases Clinic, Kampala, Uganda
Veronica Mulenga
University Teaching Hospital, Lusaka, Zambia
Elaine J. Abrams
ICAP, Mailman School of Public Health and College of Physicians & Surgeons, Columbia University, New York, New York, United States of America

Corresponding Author

Email: a.prendergast@qmul.ac.uk

Competing Interests

AP is a co-investigator on the PEHSS and ARROW trials but did not receive any funds for participation in these trials. MP has been supported by the European Union (EU; FP7) through the Paediatric European Network for the Treatment of AIDS Foundation for the past three years and is currently working as a consultant for the HIV Department at the World Health Organization (WHO). MC was a co-investigator on the P1060 and CHER trials and funds for the P1060 trial contributed to MC's salary. MC is an investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) group, funded through the Division of AIDS (DAIDS), National Institute of Allergy & Infectious Diseases (NIAID). MC has been an investigator for pharmaceutical trials for BMS and GSK from 2008 to present; funds provide site support but no contribution to his salary. MC is a member of Essential Drug list committee for children in public hospitals (2008–2012) and the Paediatric Expert Group for National Department of Health and HIV Clinicians Society of Southern Africa. MC is a member of the WHO technical task team for paediatric ARV guidelines; attended meetings from 2006 to 2008; and still contributes opinions by email. PM is a co-investigator on the ARROW trial and receives funding from DAIDS and MRC UK for this work. VM is an investigator on the CHAPAS 3 trial and receives a project management allowance for her work. VM is a member of the WHO Paediatric Antiretroviral Working Group (PAWG) committee; travel to a PAWG meeting was paid for by WHO in October 2011. EJA is a co-investigator on the P1060 and NEVEREST trials and funds from the NEVEREST trial contribute to EJA's salary. EJA is an investigator for the IMPAACT group, funded through DAIDS, NIAID. EJA is Chair of the HIV Treatment Committee, IMPAACT group. EJA receives partial salary support from NIAID for her role as Chair and medications for studies are generally donated. EJA is a member of the US Public Health Service (USPHS) guidelines committee for antiretroviral treatment of children and co-Chair of the WHO Antiretroviral Guidelines Committee. She receives no financial support for these activities. DMG is a co-investigator on the ARROW trial and receives funding from the MRC UK, DFID, EDCTP, and EU (FP7). DMG has been Chair of Data Monitoring Committees for industry paediatric trials undertaken by Tibotec (now finished). AP, MP, EJA, and DMG are members of the WHO paediatric ARV working group but receive no financial support for this activity.

Author Contributions

Wrote the first draft of the manuscript: AP MP DMG. Contributed to the writing of the manuscript: MC PM VM EJA. ICMJE criteria for authorship read and met: AP MP MC PM VM EJA DMG. Agree with manuscript results and conclusions: AP MP MC PM VM EJA DMG.